Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
David R. Koes is an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh, affiliated with the School of Medicine. He holds roles such as Associate Director of the Joint CMU-Pitt Computational Biology PhD Program (CPCB) and is involved in multiple graduate programs including Intelligent Systems and Computational Biomedicine. His research focuses on developing computational algorithms and systems for drug discovery, emphasizing open-source software and machine learning applications in biomedical data. Koes teaches courses like MSCBIO2025 (Bioinformatics Programming in Python) and MSCBIO2065 (Scalable Machine Learning for Big Data Biology). He has secured NIH funding (R35GM140753) and collaborated on projects with institutions like NVIDIA and Google Cloud. His lab develops tools such as GNINA, Pharmit, and 3Dmol.js, and actively contributes to open drug discovery initiatives. Education: PhD in Computer Science from Carnegie Mellon University (CMU). Research Interests: Leveraging computation and AI for drug design, molecular docking, pharmacophore modeling, and open science. Specific areas include developing scalable machine learning pipelines, virtual screening systems, and tools for 3D molecular analysis. Grants and Funding: Current NIH R35 grant and prior support from NSF, Relay Therapeutics, and others. His work emphasizes translating computational methods into practical drug discovery solutions. Lab and Teams: Directs a lab focused on computational drug discovery, collaborating with multiple academic and industry partners. Supervises graduate students and postdocs in projects spanning AI-driven drug design, molecular modeling, and software development.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
John D Brennan is a Professor in the Department of Chemistry & Chemical Biology at McMaster University. He is affiliated with the Biointerfaces Institute and focuses on developing innovative biosensing technologies and functional nucleic acid-based assays. His research integrates materials science, biochemistry, and analytical chemistry to create practical diagnostic tools for healthcare applications. Key research areas include the design of DNA aptamers and DNAzymes for detecting biomarkers (e.g., eosinophil peroxidase, SARS-CoV-2 spike proteins), development of paper-based diagnostic platforms, and optimization of sol-gel materials for enzyme entrapment. His work emphasizes high-throughput screening, point-of-care testing, and CRISPR-based biosensing systems. Notable contributions include a rapid sputum-based assay for asthma biomarkers and a universal DNA aptamer for SARS-CoV-2 variants. His lab also explores functional nucleic acid circuits and their integration into scalable diagnostic devices. Brennan’s teaching includes advanced courses in analytical chemistry and biochemical assay development. His work has been featured in journals like *Angewandte Chemie*, *Analytical Chemistry*, and *ChemBioChem*, with a focus on translating fundamental research into practical clinical applications.
Rhenish Friedrich Wilhelm University of BonnGermany
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Ron Dror is the Cheriton Family Professor of Computer Science at the Stanford Artificial Intelligence Lab , with courtesy appointments in Structural Biology and Molecular & Cellular Physiology . He also holds affiliations with Bio-X, the Institute for Human-Centered Artificial Intelligence (HAI), the Institute for Computational and Mathematical Engineering (ICME), Sarafan ChEM-H, and the Wu Tsai Neurosciences Institute. Education: PhD in Electrical Engineering and Computer Science, MIT MPhil in Biological Sciences, University of Cambridge (Churchill Scholar) BS in Mathematics and Electrical & Computer Engineering, Rice University (summa cum laude) Ron leads a multidisciplinary research group that combines molecular simulation and machine learning to study biomolecular structure, dynamics, and function. His work focuses on developing computational methods to accelerate drug discovery by predicting molecular interactions and designing more effective therapeutics. Current projects include the PENSA software library for analyzing biomolecular ensembles and FRAME framework for structure-based ligand design. His research has produced groundbreaking work on G-protein-coupled receptors (GPCRs) , RNA structure prediction , and mitochondrial transport mechanisms . Key publications highlight applications of geometric deep learning and molecular dynamics simulations in structural biology. Scientific Awards: Cheriton Family Professorship (2023) Two Gordon Bell Prizes (2014, 2009) Best Paper Awards at NeurIPS (2021), IPDPS (2013), SC11 (2011), SC09 (2009), SC06 (2006) Science Magazine Top 10 Breakthrough (2010) Fulbright Scholarship , NSF Fellowship , DoD Fellowship , Whitaker Foundation Fellowship Ron has advised numerous doctoral and master’s students including EJ Fine , Masha Karelina , and Briana Sobecks . His lab collaborates with experimentalists across academia and industry, applying computational methods to diverse biomedical problems such as RNA structure prediction , GPCR signaling , and mitochondrial metabolism .
Sunitha Nagrath is a Professor of Chemical Engineering at the University of Michigan, leading the Nagrath Lab. Her research focuses on developing microfluidic and nanotechnology-based tools to isolate and analyze circulating tumor cells (CTCs) and extracellular vesicles (EVs) for cancer diagnostics and personalized medicine. She holds an AIMBE Fellowship and has pioneered technologies like the Graphene Oxide Chip and Microfluidic Labyrinth. Education PhD in Mechanical Engineering, Rensselaer Polytechnic Institute (2004) MS in Nuclear Engineering, Rensselaer Polytechnic Institute (2000) B.Tech in Chemical Engineering, Sri Venkateswara University (1992) Research Interests Her lab integrates engineering, biology, and clinical expertise to study CTCs' role in metastasis, develop high-throughput isolation methods, and leverage exosomes as liquid biopsy biomarkers. Key projects include: CTC-based monitoring of therapy response in lung and pancreatic cancers Microfluidic devices for simultaneous CTC and exosome analysis Functional studies of CTC-derived organoids for drug sensitivity testing Notable Achievements AIMBE Fellow (Junior Faculty, Harvard Medical School/MGH, 2008-2010) Over 150 peer-reviewed publications and patents on CTC/exosome technologies Recipient of the 2021-22 Chemical Engineering Staff Incentive Award (via lab member Mina Zeinali) Labs & Collaborations The Nagrath Lab collaborates with clinicians and engineers to translate technologies like the OncoBean Chip and EVOD chip into clinical settings. Current work emphasizes real-time CTC monitoring and exosome-based immuno-oncology strategies.
Matthew Lakin is an Associate Professor with tenure in the Department of Computer Science at the University of New Mexico, with a courtesy appointment in the Department of Chemical & Biological Engineering. He is affiliated with the UNM Center for Biomedical Engineering and the School of Engineering, and collaborates extensively with the UNM Health Sciences Center and external institutions. Education: Ph.D., Computer Science, University of Cambridge, 2010 M.A. (Cantab), University of Cambridge, 2009 B.A. (Hons), Computer Science, University of Cambridge, 2005 Dr. Lakin's research focuses on molecular computing, DNA nanotechnology, synthetic biology, and formal verification of biomolecular circuits. He develops computational models and experimental systems for programmable biological devices, especially using heterochiral DNA to enhance stability in living cells. His work spans software tools for biodesign and experimental validation in mammalian systems, with applications in nanomedicine and biosensing. The recent publications highlight a strong trend in engineering robust, intelligent biomolecular systems. His work integrates machine learning concepts into chemical reaction networks, advances geometric modeling of DNA systems, and pioneers L-DNA-based circuits for intracellular applications. The research spans theoretical foundations, software tools, and wet-lab experimentation, emphasizing interdisciplinary innovation. Scientific Awards: Presidential Early Career Award for Scientists and Engineers (PECASE), 2025 NSF CAREER Award, 2021 UNM School of Engineering Junior Faculty Research Excellence Award, 2021 Multiple student awards under his mentorship, including the Outstanding Graduate Student Award and DNA28 Best Student Presentation recognition Dr. Lakin has advised numerous graduate and undergraduate students, including Ph.D. graduates in Biomedical Engineering and Computer Science. He leads major funded projects such as the NSF CAREER grant on heterochiral molecular computing, an EPSCoR Research Fellowship, and a $3M NSF grant on heavy metal biosensing in collaboration with Native American communities. He is also PI on multiple NSF grants related to synthetic cells and nucleic acid technologies. He directs the Lakin Lab for Programmable Biology, which operates within the Department of Computer Science and collaborates with Chemical & Biological Engineering and the Center for Biomedical Engineering. The lab emphasizes both computational modeling and experimental molecular biology, and runs an NSF-funded biotechnology summer camp in partnership with ¡Explora! science museum to strengthen STEM education in New Mexico.
Dr. Michael Baym is an Associate Professor of Biomedical Informatics at Harvard Medical School with affiliate appointments in Microbiology and the Laboratory of Systems Pharmacology, and as an Associate Member of the Broad Institute. He leads the Baym Lab, which studies microbial evolutionary genomics and antibiotic resistance through a hybrid of experimental, computational, and theoretical approaches. His research focuses on: Antibiotic Resistance Evolution and practical interventions Mobile Genetic Elements (plasmids, phages, transposons) Computational Genomic Algorithms for big data analysis Synthetic Biology tools and technologies Key recent publications explore phage discovery systems , phylogenetic compression of microbial genomes, and RNA-guided gene drives in plasmids. His work is supported by multiple NIH/NIGMS and NSF grants including a MIRA award. Scientific honors include: Packard Fellowship (2018) Pew Biomedical Scholarship (2020) Sloan Research Fellowship (2020) A. Clifford Barger Excellence in Mentoring Award (2021) SSQBio Mentorship Award (2022) The lab actively trains PhD students and postdoctoral fellows with alumni occupying academic and industry positions globally. Current team members include researchers from interdisciplinary backgrounds working at the intersection of experiment, computation, and theory .
Jeff Schorey is the George B. Craig Jr. Professor and a full Professor in the Department of Biological Sciences at the University of Notre Dame, where he has been a faculty member since 2004. He currently serves as Director of the Integrated Biomedical Sciences (IBMS) graduate program and previously held leadership roles including Chair of the Institutional Animal Care and Use Committee (IACUC) and Associate Director of the Eck Institute for Global Health. His research focuses on the pathobiology of mycobacterial diseases, particularly Mycobacterium tuberculosis and M. avium . His work investigates the molecular interactions between mycobacteria and host macrophages, with a special emphasis on the role of exosomes in immune modulation, diagnostics, and vaccine development. He also explores novel antibiotic development in collaboration with chemists at Notre Dame and global partners. His recent publications reveal a strong trend in extracellular vesicle biology, host-pathogen signaling, and translational applications in TB diagnostics and treatment. The articles span immunology, microbiology, and molecular biology, with recurring themes in exosome function, RNA sensing, and antimicrobial development. George B. Craig Jr. Collegiate Professor Dr. Schorey has advised graduate students and leads an active research lab focused on mycobacterial pathogenesis. His work is supported by collaborations across disciplines and institutions, particularly in drug development and clinical translation. He has contributed significantly to understanding how exosomes can serve as both biomarkers and therapeutic tools. His lab employs cellular immunology, animal models, and clinical sample analysis to study mycobacterial infections. He leads the IBMS program, shaping graduate education in biomedical sciences at Notre Dame.
Rahul Sarpeshkar is a Professor of Engineering, Microbiology & Immunology, Physics, and Molecular & Systems Biology at Dartmouth College, holding the Thomas E. Kurtz Professorship and chairing the Neukom Computational Science Cluster. His research bridges analog circuits with quantum physics, synthetic biology, and ultra-low-power systems. BS in Electrical Engineering and Physics from MIT (1995) PhD in Computation and Neural Systems from Caltech (1998) His research focuses on analog synthetic biology , quantum circuit design , and bio-inspired supercomputing , emphasizing noise, thermodynamics, and energy efficiency. He develops cytomorphic chips to model biochemical networks and quantum-inspired circuits for spectrum analysis. Recent work integrates quantum and classical computation for biological simulations, drug cocktail formulation , and ATP energy measurement in living cells. Patents highlight innovations in quantum emulation and medical devices. Scientific awards include: Fellow, National Academy of Inventors (2018) IEEE Fellow (2018) NSF CAREER Award ONR Young Investigator Award Packard Fellow Award Junior Bose Teaching Award, MIT He leads a wet lab for synthetic microbial circuit implementation and a dry lab for quantum and nanoelectronics, mentoring a multidisciplinary team of physicists, bioengineers, and computer scientists.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
University of North Carolina at Chapel HillUnited States
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
